Pancreatic Cancer 80 Years

Birgir Gudjonsson

Department of Medical Clinics, Reykjavik, Iceland

^*Correspondance to: Birgir Gudjonsson 

 PDF  Full Text Review Article | Open Access

Abstract:

Resections for pancreatic adenocarcinoma have now been carried out for 80 yrs. Opinions still differ as to the results. The incidence of pancreatic cancer was estimated to be 48,960 in 2015 in the US. It is projected to increase to 88,000 for both sexes in 2030 and to become the second to third leading cause of cancer-related deaths by 2030. O’Neill and colleagues studied the total direct medical cost of treatment of pancreatic patients 66 years and older who were diagnosed from 2000-2007 in the US. The total direct cost for resectable disease was $134,700, and for unresectable locoregional disease $65,300. Assuming a 2.5% inflation over 10 years, the cost in 2017 could be $172,500 for resections and for unresectable (or bypasses) $83,500.This author has scrutinized the literature on surgical results over the last 80 years, checking for the number of survivors and the overall survival percentage. Approximately 1230 papers have been found which deal with resections and reveal at least some survival information.Papers on the surgical aspects of pancreatic cancer differ as to the approach and the composition of the patient group and the method of reporting. Only papers with separate pathologic information on patients were selected for analysis. The search revealed that of these 1230 papers, only 621 papers report 5-year survivors. Special attention has been paid to the time period each study covered, patient composition, the subset of patients used for calculations and the statistical method used

Keywords:

Cite the Article:

Gudjonsson B. Pancreatic Cancer 80 Years. Clin Oncol. 2017; 2: 1339.